---
title: Hematopathology
order: 3
category: Clinical Pathology
status: complete
last_updated: '2025-01-09'
---

# Hematopathology

## Overview

Hematopathology is the subspecialty of pathology focused on diseases of blood cells, bone marrow, lymph nodes, and the coagulation system. It combines laboratory medicine with anatomic pathology, utilizing blood smears, bone marrow examination, flow cytometry, cytogenetics, and molecular diagnostics to diagnose and classify hematologic disorders. Hematopathology encompasses benign conditions such as anemias and coagulation disorders, as well as malignant diseases including leukemias and lymphomas.

### Scope of Practice
- Complete blood count interpretation
- Peripheral blood smear examination
- Bone marrow aspiration and biopsy analysis
- Flow cytometric immunophenotyping
- Hemostasis and coagulation testing
- Transfusion medicine and blood banking
- Molecular and cytogenetic diagnostics
- Hematologic malignancy classification

### Clinical Significance
- Early detection of hematologic diseases
- Diagnosis of anemias and cytopenias
- Classification of leukemias and lymphomas
- Monitoring of treatment response
- Transfusion support and compatibility testing
- Bleeding and thrombotic disorder evaluation

## Normal Hematopoiesis

### Blood Cell Development

#### Hematopoietic Stem Cells
- **Self-renewal**: Maintain stem cell pool
- **Differentiation**: Produce all blood lineages
- **Location**: Bone marrow (adults), liver/spleen (fetus)
- **Regulation**: Cytokines, growth factors, microenvironment

#### Cell Lineages
- **Myeloid**: Erythrocytes, granulocytes, monocytes, platelets
- **Lymphoid**: T cells, B cells, NK cells
- **Common progenitors**: CFU-GEMM, CFU-GM, BFU-E, CFU-Meg

### Growth Factors and Cytokines
- **Erythropoietin (EPO)**: Red blood cell production
- **Granulocyte colony-stimulating factor (G-CSF)**: Neutrophil production
- **Thrombopoietin (TPO)**: Platelet production
- **Interleukins**: Various lineage effects
- **Stem cell factor (SCF)**: Early progenitor support

### Bone Marrow Structure
- **Cellular compartment**: Hematopoietic cells
- **Stromal compartment**: Support cells, extracellular matrix
- **Vascular sinusoids**: Cell release into circulation
- **Normal cellularity**: Age-dependent (100-age in years)
- **M:E ratio**: Myeloid to erythroid ratio (3:1 to 4:1)

## Complete Blood Count (CBC)

### Red Blood Cell Parameters

#### Hemoglobin (Hgb)
- **Normal values**: Males 13.5-17.5 g/dL, Females 12-16 g/dL
- **Function**: Oxygen transport
- **Decreased**: Anemia
- **Increased**: Polycythemia

#### Hematocrit (Hct)
- **Definition**: Volume percentage of red blood cells
- **Normal values**: Males 39-51%, Females 36-47%
- **Calculation**: Approximately 3× hemoglobin

#### Red Blood Cell Count (RBC)
- **Normal values**: Males 4.5-5.9 million/μL, Females 4.1-5.1 million/μL
- **Clinical utility**: Limited alone, used in calculations

#### Red Cell Indices

##### Mean Corpuscular Volume (MCV)
- **Definition**: Average red cell size
- **Normal range**: 80-100 fL
- **Microcytic**: <80 fL (iron deficiency, thalassemia)
- **Normocytic**: 80-100 fL (acute blood loss, chronic disease)
- **Macrocytic**: >100 fL (B12/folate deficiency, liver disease)

##### Mean Corpuscular Hemoglobin (MCH)
- **Definition**: Average hemoglobin per red cell
- **Normal range**: 27-33 pg
- **Parallels MCV changes**

##### Mean Corpuscular Hemoglobin Concentration (MCHC)
- **Definition**: Average hemoglobin concentration
- **Normal range**: 32-36 g/dL
- **Decreased**: Hypochromic (iron deficiency)
- **Increased**: Spherocytosis, artifact

##### Red Cell Distribution Width (RDW)
- **Definition**: Variation in red cell size
- **Normal range**: 11.5-14.5%
- **Increased**: Anisocytosis, mixed deficiencies
- **Diagnostic utility**: Distinguish causes of anemia

#### Reticulocyte Count
- **Definition**: Young red blood cells
- **Normal range**: 0.5-2.5% or 25,000-75,000/μL
- **Increased**: Hemolysis, blood loss, response to treatment
- **Decreased**: Bone marrow failure, nutritional deficiency
- **Corrected count**: Adjusts for degree of anemia
- **Reticulocyte production index (RPI)**: Adjusts for maturation time

### White Blood Cell Parameters

#### Total White Blood Cell Count (WBC)
- **Normal range**: 4,500-11,000/μL
- **Leukocytosis**: Increased count
- **Leukopenia**: Decreased count

#### Differential Count

##### Neutrophils
- **Normal range**: 40-70% (2,000-7,500/μL)
- **Increased**: Infection, inflammation, stress, malignancy
- **Decreased**: Bone marrow failure, drugs, autoimmune
- **Left shift**: Increased immature forms (bands)

##### Lymphocytes
- **Normal range**: 20-40% (1,000-4,000/μL)
- **Increased**: Viral infections, chronic lymphocytic leukemia
- **Decreased**: Immunodeficiency, steroids, stress

##### Monocytes
- **Normal range**: 2-10% (200-1,000/μL)
- **Increased**: Chronic infections, inflammatory conditions
- **Clinical significance**: Phagocytic cells

##### Eosinophils
- **Normal range**: 1-4% (50-400/μL)
- **Increased**: Allergies, parasites, drugs, malignancy
- **Hypereosinophilia**: >1,500/μL

##### Basophils
- **Normal range**: 0-1% (0-100/μL)
- **Increased**: Myeloproliferative disorders, hypersensitivity
- **Rare in peripheral blood**

### Platelet Parameters

#### Platelet Count
- **Normal range**: 150,000-400,000/μL
- **Thrombocytosis**: >450,000/μL
- **Thrombocytopenia**: <150,000/μL
- **Critical low**: <50,000/μL (bleeding risk)
- **Severe**: <20,000/μL (spontaneous bleeding)

#### Mean Platelet Volume (MPV)
- **Normal range**: 7-11 fL
- **Increased**: Young platelets, increased production
- **Decreased**: Bone marrow disorders

## Anemias

### Classification of Anemia

#### By Mechanism
- **Decreased production**: Nutritional, bone marrow failure
- **Increased destruction**: Hemolysis
- **Blood loss**: Acute or chronic hemorrhage
- **Sequestration**: Hypersplenism

#### By Morphology (MCV)
- **Microcytic**: Iron deficiency, thalassemia, anemia of chronic disease
- **Normocytic**: Acute blood loss, hemolysis, chronic disease, renal failure
- **Macrocytic**: B12/folate deficiency, liver disease, hypothyroidism

### Iron Deficiency Anemia

#### Pathophysiology
- Inadequate iron for hemoglobin synthesis
- Depleted iron stores (low ferritin)
- Decreased serum iron, increased TIBC
- Progressive microcytic, hypochromic anemia

#### Causes
- **Blood loss**: GI bleeding, menstruation
- **Inadequate intake**: Poor diet, malabsorption
- **Increased demand**: Pregnancy, growth
- **Chronic disease**: Inflammatory bowel disease

#### Laboratory Features
- Low MCV, low MCHC
- Low serum iron, low ferritin
- High TIBC, low transferrin saturation (<15%)
- Increased RDW
- Peripheral smear: Microcytic, hypochromic, pencil cells

#### Treatment Response
- Reticulocytosis in 5-10 days
- Hemoglobin rise in 2-4 weeks
- Ferritin normalization in 1-3 months
- Continue therapy to replete stores

### Megaloblastic Anemia

#### Vitamin B12 Deficiency
- **Causes**: Pernicious anemia, malabsorption, dietary deficiency
- **Pathophysiology**: Impaired DNA synthesis, nuclear-cytoplasmic asynchrony
- **Features**: Macrocytic anemia, hypersegmented neutrophils, pancytopenia
- **Neurological**: Subacute combined degeneration (if B12)
- **Laboratory**: Low B12, elevated methylmalonic acid, homocysteine

#### Folate Deficiency
- **Causes**: Poor nutrition, malabsorption, increased demand, drugs
- **Pathophysiology**: Similar to B12 deficiency
- **Features**: Macrocytic anemia, no neurological symptoms
- **Laboratory**: Low folate, elevated homocysteine (normal MMA)

#### Peripheral Smear
- Macro-ovalocytes
- Hypersegmented neutrophils (>5 lobes)
- Pancytopenia in severe cases
- Giant platelets

### Hemolytic Anemias

#### General Features
- **Increased RBC destruction**: Shortened red cell lifespan
- **Compensatory response**: Reticulocytosis, marrow hyperplasia
- **Laboratory**: Elevated LD, indirect bilirubin, decreased haptoglobin
- **Peripheral smear**: Polychromasia, nucleated RBCs, specific morphology

#### Intrinsic Defects

##### Hereditary Spherocytosis
- **Defect**: Membrane protein deficiency (spectrin, ankyrin)
- **Features**: Spherocytes, osmotic fragility, splenomegaly
- **Complications**: Gallstones, aplastic crisis
- **Treatment**: Splenectomy for severe cases

##### Glucose-6-Phosphate Dehydrogenase Deficiency
- **Defect**: G6PD enzyme deficiency
- **Inheritance**: X-linked recessive
- **Triggers**: Oxidant drugs, fava beans, infection
- **Features**: Episodic hemolysis, bite cells, Heinz bodies
- **Management**: Avoid triggers

##### Sickle Cell Disease
- **Defect**: HbS (β-globin mutation, Glu6Val)
- **Pathophysiology**: RBC sickling under hypoxia
- **Features**: Vaso-occlusive crises, chronic hemolysis
- **Complications**: Stroke, acute chest syndrome, splenic infarction
- **Laboratory**: Sickle cells, target cells, positive sickle test
- **Diagnosis**: Hemoglobin electrophoresis

##### Thalassemias
- **α-Thalassemia**: Deletion of α-globin genes (4 genes total)
- **β-Thalassemia**: Mutations in β-globin gene
- **Features**: Microcytic anemia, target cells, basophilic stippling
- **Severity**: Depends on number of genes affected
- **Treatment**: Transfusions, iron chelation, splenectomy

#### Extrinsic Defects

##### Autoimmune Hemolytic Anemia
- **Warm AIHA**: IgG antibodies, extravascular hemolysis
- **Cold AIHA**: IgM antibodies, complement activation
- **Direct antiglobulin test (DAT)**: Positive
- **Treatment**: Steroids, immunosuppression, splenectomy

##### Microangiopathic Hemolytic Anemia
- **Causes**: TTP, HUS, DIC, mechanical heart valves
- **Mechanism**: Mechanical RBC fragmentation
- **Features**: Schistocytes, thrombocytopenia
- **Laboratory**: Hemolysis markers, negative DAT

### Anemia of Chronic Disease
- **Pathophysiology**: Hepcidin-mediated iron sequestration
- **Causes**: Infection, inflammation, malignancy
- **Features**: Normocytic or mildly microcytic
- **Laboratory**: Low iron, low/normal TIBC, elevated ferritin
- **Treatment**: Address underlying condition

### Aplastic Anemia
- **Definition**: Bone marrow failure, pancytopenia
- **Causes**: Idiopathic, drugs, toxins, viruses, radiation
- **Features**: Severe anemia, neutropenia, thrombocytopenia
- **Bone marrow**: Hypocellular with fat replacement
- **Treatment**: Immunosuppression, stem cell transplant

## Leukemias

### Acute Leukemias

#### Acute Myeloid Leukemia (AML)

##### Classification (WHO 2016)
- AML with recurrent genetic abnormalities
- AML with myelodysplasia-related changes
- Therapy-related AML
- AML not otherwise specified

##### Clinical Features
- **Symptoms**: Fatigue, infections, bleeding
- **Signs**: Pallor, fever, petechiae, organomegaly
- **Age**: Median 68 years, increases with age

##### Laboratory Features
- **CBC**: Anemia, thrombocytopenia, variable WBC
- **Peripheral smear**: Blasts (>20% diagnostic)
- **Bone marrow**: Hypercellular, >20% blasts
- **Flow cytometry**: Myeloid markers (CD13, CD33, CD117, MPO)
- **Cytogenetics**: Prognostic significance

##### Important Subtypes
- **AML with t(15;17)**: Acute promyelocytic leukemia (APL)
- **AML with inv(16) or t(16;16)**: Good prognosis
- **AML with t(8;21)**: Good prognosis
- **AML with complex karyotype**: Poor prognosis

##### Acute Promyelocytic Leukemia (APL)
- **Genetics**: t(15;17), PML-RARA fusion
- **Features**: Abnormal promyelocytes, DIC
- **Treatment**: ATRA (all-trans retinoic acid), arsenic trioxide
- **Prognosis**: Excellent with modern therapy

#### Acute Lymphoblastic Leukemia (ALL)

##### Classification
- **B-lymphoblastic leukemia/lymphoma**: Most common (75%)
- **T-lymphoblastic leukemia/lymphoma**: 25%
- **Subtypes by genetic abnormalities**

##### Clinical Features
- **Age**: Peak in children 2-5 years
- **Symptoms**: Similar to AML
- **CNS involvement**: More common than AML
- **Mediastinal mass**: T-ALL

##### Laboratory Features
- **CBC**: Anemia, thrombocytopenia, lymphoblastosis
- **Peripheral smear**: Lymphoblasts
- **Bone marrow**: >20% lymphoblasts
- **Flow cytometry**:
  - B-ALL: CD19, CD10, TdT, CD34
  - T-ALL: CD2, CD3, CD5, CD7, TdT
- **Cytogenetics**:
  - t(12;21): Favorable (children)
  - t(9;22): BCR-ABL, Philadelphia chromosome (poor prognosis)
  - Hyperdiploidy: Favorable

##### Prognosis
- **Children**: >90% cure rate
- **Adults**: ~40% cure rate
- **Philadelphia chromosome positive**: Improved with tyrosine kinase inhibitors

### Chronic Leukemias

#### Chronic Myeloid Leukemia (CML)

##### Genetics
- **Philadelphia chromosome**: t(9;22), BCR-ABL1 fusion
- **Tyrosine kinase**: Constitutive activation, proliferation
- **Diagnostic**: >95% of CML cases

##### Clinical Phases
- **Chronic phase**: Insidious onset, 85% at diagnosis
- **Accelerated phase**: Increasing blasts, cytopenia, evolution
- **Blast phase**: >20% blasts, acute leukemia transformation

##### Laboratory Features
- **CBC**: Marked leukocytosis (often >100,000/μL)
- **Peripheral smear**: Entire myeloid maturation spectrum
- **Bone marrow**: Hypercellular, myeloid predominance
- **Basophilia and eosinophilia**: Characteristic
- **Low leukocyte alkaline phosphatase (LAP)**: Distinguishes from leukemoid reaction

##### Treatment
- **Tyrosine kinase inhibitors (TKIs)**: Imatinib, dasatinib, nilotinib
- **Monitoring**: BCR-ABL1 quantification by PCR
- **Response**: Hematologic, cytogenetic, molecular
- **Prognosis**: Excellent with TKIs, near-normal life expectancy

#### Chronic Lymphocytic Leukemia (CLL)

##### Definition
- Clonal proliferation of mature B lymphocytes
- Most common leukemia in Western adults
- Median age: 70 years

##### Clinical Features
- **Asymptomatic**: Often incidental finding
- **Lymphadenopathy**: Painless, generalized
- **Hepatosplenomegaly**: Common
- **Infections**: Hypogammaglobulinemia
- **Autoimmune complications**: AIHA, ITP

##### Laboratory Features
- **CBC**: Lymphocytosis (>5,000/μL required for diagnosis)
- **Peripheral smear**: Small, mature lymphocytes, smudge cells
- **Immunophenotype**: CD5+, CD19+, CD20+ (dim), CD23+
- **Bone marrow**: Lymphocytic infiltration
- **Monoclonal B cells**: Essential for diagnosis

##### Prognostic Factors
- **Rai staging**: 0 (lymphocytosis) to IV (thrombocytopenia)
- **Binet staging**: A (< 3 areas) to C (anemia/thrombocytopenia)
- **Cytogenetics**:
  - del(13q): Favorable
  - Normal: Intermediate
  - Trisomy 12: Intermediate
  - del(11q): Unfavorable
  - del(17p): Very unfavorable
- **IGHV mutation status**: Mutated = favorable
- **ZAP-70, CD38 expression**: Unfavorable if positive

##### Treatment
- **Watch and wait**: Early stage, asymptomatic
- **Chemoimmunotherapy**: Fludarabine, cyclophosphamide, rituximab (FCR)
- **Targeted therapy**: Ibrutinib, venetoclax
- **Indications**: Progressive disease, symptomatic, cytopenias

## Lymphomas

### Hodgkin Lymphoma

#### Classification
- **Classical Hodgkin lymphoma (95%)**:
  - Nodular sclerosis (most common, mediastinal)
  - Mixed cellularity (HIV, elderly)
  - Lymphocyte-rich
  - Lymphocyte-depleted (rare, poor prognosis)
- **Nodular lymphocyte-predominant Hodgkin lymphoma (5%)**

#### Pathology
- **Reed-Sternberg cells**: Large, binucleate/multilobate, prominent nucleoli
- **Background**: Reactive inflammatory cells
- **Immunophenotype**: CD15+, CD30+, CD20- (classical)

#### Clinical Features
- **Bimodal age**: 15-35 years, >55 years
- **Lymphadenopathy**: Painless, often cervical
- **B symptoms**: Fever, night sweats, weight loss
- **Mediastinal mass**: Common in nodular sclerosis

#### Staging (Ann Arbor)
- **Stage I**: Single lymph node region
- **Stage II**: ≥2 lymph node regions, same side of diaphragm
- **Stage III**: Lymph nodes both sides of diaphragm
- **Stage IV**: Disseminated, extranodal involvement

#### Treatment and Prognosis
- **Early stage**: ABVD chemotherapy ± radiation
- **Advanced stage**: ABVD or escalated BEACOPP
- **Cure rate**: 80-90% overall
- **Poor prognostic factors**: Bulky disease, B symptoms, advanced stage

### Non-Hodgkin Lymphoma

#### Classification (WHO 2016)
- **B-cell lymphomas (85%)**
- **T-cell and NK-cell lymphomas (15%)**
- **Indolent vs. aggressive**

#### Diffuse Large B-Cell Lymphoma (DLBCL)

##### Features
- **Most common NHL**: ~30% of cases
- **Aggressive**: Rapid growth, symptomatic
- **Age**: Median 70 years
- **Sites**: Nodal and extranodal

##### Pathology
- **Architecture**: Diffuse effacement
- **Cells**: Large B cells, variable morphology
- **Immunophenotype**: CD19+, CD20+, CD79a+
- **Subtypes**: Germinal center B-cell, activated B-cell

##### Treatment
- **R-CHOP**: Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
- **Cure rate**: 60-70%
- **CNS prophylaxis**: High-risk cases

#### Follicular Lymphoma

##### Features
- **Second most common NHL**: ~20% of cases
- **Indolent**: Slow-growing, waxing/waning
- **Age**: Median 60 years
- **Generalized lymphadenopathy**

##### Pathology
- **Architecture**: Follicular pattern
- **Cells**: Small cleaved cells, centrocytes
- **Genetics**: t(14;18), BCL2 overexpression
- **Grading**: Based on large cells/HPF

##### Treatment
- **Watch and wait**: Asymptomatic, low burden
- **Rituximab**: Single agent or with chemotherapy
- **Radiation**: Localized disease
- **Transformation**: 2-3% per year to DLBCL

#### Mantle Cell Lymphoma

##### Features
- **Aggressive with poor prognosis**
- **Age**: Median 60 years, male predominance
- **Sites**: Lymph nodes, spleen, GI tract

##### Pathology
- **Cells**: Small to medium lymphocytes
- **Genetics**: t(11;14), cyclin D1 overexpression
- **Immunophenotype**: CD5+, CD20+, CD23-, cyclin D1+

##### Treatment
- **Intensive chemotherapy**: Hyper-CVAD, high-dose cytarabine
- **Stem cell transplant**: Consolidation
- **Maintenance rituximab**: Prolongs remission
- **Median survival**: 5-7 years

#### Burkitt Lymphoma

##### Features
- **Highly aggressive**: Doubling time <24 hours
- **Variants**: Endemic (Africa, jaw), sporadic (abdomen), HIV-associated
- **"Starry sky" pattern**: Tingible body macrophages

##### Pathology
- **Cells**: Uniform medium-sized cells
- **Genetics**: MYC translocation t(8;14), t(2;8), or t(8;22)
- **Immunophenotype**: CD19+, CD20+, CD10+, BCL2-, Ki-67 ~100%

##### Treatment
- **Intensive chemotherapy**: High-dose methotrexate, cytarabine
- **CNS prophylaxis**: Mandatory
- **Cure rate**: 70-90% (children), 50% (adults)

## Myeloproliferative Neoplasms

### Polycythemia Vera (PV)

#### Features
- **Clonal disorder**: Increased red cell mass
- **JAK2 V617F mutation**: >95% of cases
- **Clinical**: Headache, pruritus, thrombosis, bleeding
- **Complications**: Thrombosis, transformation to myelofibrosis or AML

#### Diagnostic Criteria (WHO)
- **Major**: Elevated Hgb/Hct, JAK2 mutation, bone marrow hypercellularity
- **Minor**: Low erythropoietin

#### Treatment
- **Phlebotomy**: Maintain Hct <45%
- **Aspirin**: Reduce thrombosis
- **Hydroxyurea**: High-risk patients

### Essential Thrombocythemia (ET)

#### Features
- **Sustained thrombocytosis**: Platelets >450,000/μL
- **Mutations**: JAK2 (50%), CALR (25%), MPL (5%)
- **Complications**: Thrombosis, bleeding (paradoxical)
- **Age**: Median 50-60 years

#### Treatment
- **Low-risk**: Aspirin alone
- **High-risk**: Cytoreductive therapy (hydroxyurea)

### Primary Myelofibrosis

#### Features
- **Bone marrow fibrosis**: Progressive
- **Extramedullary hematopoiesis**: Splenomegaly
- **Leukoerythroblastic blood picture**
- **Tear drop cells**: Characteristic

#### Prognosis
- **Variable**: Months to years
- **Transformation**: AML in 10-20%
- **Treatment**: Supportive, JAK inhibitors, transplant

## Coagulation Disorders

### Hemostasis Overview

#### Primary Hemostasis
- **Platelet adhesion**: von Willebrand factor, collagen
- **Platelet activation**: ADP, thromboxane A2
- **Platelet aggregation**: Fibrinogen, GPIIb/IIIa
- **Result**: Platelet plug

#### Secondary Hemostasis
- **Coagulation cascade**: Intrinsic and extrinsic pathways
- **Common pathway**: Factor X → thrombin → fibrin
- **Fibrin clot**: Stabilized by factor XIII

#### Fibrinolysis
- **Plasminogen → plasmin**: tPA activation
- **Fibrin degradation**: D-dimer formation
- **Regulation**: PAI-1, α2-antiplasmin

### Coagulation Testing

#### Prothrombin Time (PT/INR)
- **Measures**: Extrinsic and common pathways (VII, X, V, II, fibrinogen)
- **INR**: International normalized ratio, standardized
- **Prolonged**: Warfarin, liver disease, vitamin K deficiency, factor VII deficiency
- **Monitoring**: Warfarin therapy (target INR 2-3)

#### Activated Partial Thromboplastin Time (aPTT)
- **Measures**: Intrinsic and common pathways (XII, XI, IX, VIII, X, V, II, fibrinogen)
- **Prolonged**: Heparin, hemophilia, von Willebrand disease, lupus anticoagulant
- **Monitoring**: Heparin therapy

#### Thrombin Time (TT)
- **Measures**: Fibrinogen → fibrin conversion
- **Prolonged**: Heparin, hypofibrinogenemia, dysfibrinogenemia

#### Mixing Studies
- **Procedure**: Mix patient plasma 1:1 with normal plasma
- **Correction**: Factor deficiency
- **No correction**: Inhibitor present

### Bleeding Disorders

#### Hemophilia A
- **Deficiency**: Factor VIII
- **Inheritance**: X-linked recessive
- **Severity**: Based on factor level (<1% severe)
- **Clinical**: Hemarthrosis, muscle bleeds, CNS hemorrhage
- **Laboratory**: Prolonged aPTT, normal PT, low factor VIII
- **Treatment**: Factor VIII replacement

#### Hemophilia B
- **Deficiency**: Factor IX (Christmas disease)
- **Inheritance**: X-linked recessive
- **Similar to hemophilia A**
- **Treatment**: Factor IX replacement

#### von Willebrand Disease
- **Most common inherited bleeding disorder**: 1% population
- **Types**:
  - Type 1: Partial quantitative deficiency (most common)
  - Type 2: Qualitative defect
  - Type 3: Complete deficiency (rare)
- **Function**: Platelet adhesion, factor VIII carrier
- **Laboratory**: Prolonged aPTT (variable), low vWF antigen/activity
- **Treatment**: Desmopressin (DDAVP), vWF concentrate

### Thrombotic Disorders

#### Inherited Thrombophilias
- **Factor V Leiden**: Activated protein C resistance
- **Prothrombin G20210A**: Elevated prothrombin levels
- **Protein C deficiency**: Natural anticoagulant
- **Protein S deficiency**: Cofactor for protein C
- **Antithrombin deficiency**: Inhibits thrombin, factor Xa

#### Acquired Thrombophilias
- **Antiphospholipid syndrome**: Lupus anticoagulant, anticardiolipin antibodies
- **Malignancy**: Trousseau syndrome
- **Pregnancy and oral contraceptives**: Hypercoagulable state
- **Surgery and immobility**: Venous stasis

### Disseminated Intravascular Coagulation (DIC)

#### Pathophysiology
- **Trigger**: Tissue factor release, endothelial damage
- **Activation**: Coagulation cascade, platelet activation
- **Consumption**: Coagulation factors, platelets
- **Fibrinolysis**: Secondary activation
- **Result**: Bleeding and thrombosis

#### Causes
- **Sepsis**: Most common
- **Trauma**: Tissue damage
- **Malignancy**: APL, adenocarcinomas
- **Obstetric**: Amniotic fluid embolism, abruption

#### Laboratory Features
- **Thrombocytopenia**: Consumption
- **Prolonged PT/aPTT**: Factor consumption
- **Low fibrinogen**: Consumption
- **Elevated D-dimer**: Fibrinolysis
- **Schistocytes**: Microangiopathic hemolysis

#### Treatment
- **Address underlying cause**: Critical
- **Supportive**: Platelets, FFP, cryoprecipitate
- **Anticoagulation**: In thrombotic DIC

## Transfusion Medicine

### Blood Components

#### Red Blood Cells (RBCs)
- **Use**: Symptomatic anemia, acute blood loss
- **Threshold**: Hgb <7 g/dL (restrictive), <8 g/dL (cardiac patients)
- **Dose**: Raises Hgb ~1 g/dL per unit
- **Storage**: 35-42 days at 1-6°C

#### Platelets
- **Use**: Bleeding, thrombocytopenia, platelet dysfunction
- **Prophylactic threshold**: <10,000/μL (stable), <50,000/μL (procedures)
- **Dose**: Raises platelet count ~30,000-60,000/μL
- **Storage**: 5 days at 20-24°C with agitation

#### Fresh Frozen Plasma (FFP)
- **Use**: Coagulation factor replacement, TTP
- **Contains**: All coagulation factors
- **Dose**: 10-20 mL/kg
- **Storage**: 1 year frozen, 24 hours after thawing

#### Cryoprecipitate
- **Contains**: Fibrinogen, factor VIII, vWF, factor XIII
- **Use**: Hypofibrinogenemia, uremic bleeding
- **Dose**: 1-2 units/10 kg

### Blood Typing and Compatibility

#### ABO Blood Group
- **A antigen**: Anti-B antibodies
- **B antigen**: Anti-A antibodies
- **AB**: Both antigens, no antibodies (universal recipient)
- **O**: No antigens, both antibodies (universal donor)

#### Rh System
- **Rh positive**: D antigen present
- **Rh negative**: D antigen absent
- **Anti-D**: Can develop after exposure (transfusion, pregnancy)

#### Compatibility Testing
- **Type and screen**: ABO/Rh, antibody screen
- **Crossmatch**: Donor RBCs + recipient serum
- **Major crossmatch**: Detects antibodies to donor RBCs
- **Electronic crossmatch**: ABO compatible, negative antibody screen

### Transfusion Reactions

#### Acute Hemolytic
- **Cause**: ABO incompatibility
- **Timing**: Minutes to hours
- **Symptoms**: Fever, chills, pain, shock, DIC
- **Management**: Stop transfusion, supportive care

#### Febrile Non-Hemolytic
- **Cause**: Cytokines, leukocyte antibodies
- **Timing**: During or after transfusion
- **Symptoms**: Fever, chills
- **Prevention**: Leukoreduction

#### Allergic
- **Cause**: Plasma proteins
- **Symptoms**: Urticaria, pruritus
- **Severe**: Anaphylaxis
- **Prevention**: Washed RBCs, IgA-deficient products

#### Transfusion-Related Acute Lung Injury (TRALI)
- **Cause**: Donor antibodies, bioactive lipids
- **Timing**: Within 6 hours
- **Symptoms**: Respiratory distress, bilateral infiltrates
- **Management**: Supportive, mechanical ventilation

## Key Points

- Complete blood count provides essential information for diagnosing hematologic disorders
- Anemia classification by MCV guides differential diagnosis and evaluation
- Reticulocyte count distinguishes production defects from increased destruction
- Acute leukemias require >20% blasts in blood or bone marrow for diagnosis
- Flow cytometry is essential for immunophenotyping and classifying hematologic malignancies
- CML is characterized by Philadelphia chromosome (BCR-ABL1 fusion) and treated with TKIs
- Hodgkin lymphoma is distinguished by Reed-Sternberg cells and has excellent cure rates
- Non-Hodgkin lymphomas are diverse, classified by cell of origin and clinical behavior
- Coagulation testing evaluates different components of the hemostatic system
- Transfusion medicine requires careful blood typing and compatibility testing to prevent reactions

## References

1. Hoffman R, Benz EJ, Silberstein LE, et al. Hematology: Basic Principles and Practice. 8th ed. Elsevier; 2023.
2. Kaushansky K, Lichtman MA, Prchal JT, et al. Williams Hematology. 10th ed. McGraw-Hill; 2021.
3. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. IARC; 2017.
4. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
5. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. 2024.
6. American Society of Hematology. Self-Assessment Program. 7th ed. 2023.
7. College of American Pathologists. Hematology and Clinical Microscopy Resource Committee. 2024.
8. Rodak BF, Fritsma GA, Keohane EM. Hematology: Clinical Principles and Applications. 6th ed. Elsevier; 2020.
9. Harmening DM. Clinical Hematology and Fundamentals of Hemostasis. 6th ed. FA Davis; 2019.
10. Fung MK, Eder AF, Spitalnik SL, Westhoff CM. Technical Manual. 20th ed. AABB; 2020.
